Recognising and managing skin conditions in children on biologic therapies

Dr Tess McPherson, a leading paediatric dermatologist at Oxford University Hospitals, provides insights into the latest research and development in the recognition and management of skin conditions in children and young people receiving biologic therapies for inflammatory conditions such as inflammatory bowel disease. The discussion highlights the increasing prevalence of significant skin problems among patients treated with biologics—previously described as paradoxical psoriasis, but now recognized as an expected complication in a proportion of young people. Dr McPherson emphasises the importance of early recognition, patient counselling about potential skin issues, and collaborative management with dermatologists, which may involve topical treatments or adjustments to medication. She also discusses how these findings are improving our understanding of immune pathway alterations caused by new medications and the need for multidisciplinary teamwork to inform and support patients and families. This interview took place at the RCPCH conference 2025 in Glasgow, Scotland.